Biosimilars for Tysabri: A Guide for Crohn's Disease

Tysabri occupies a specialized place in Crohn's disease treatment because it is reserved for certain adults and is distributed through a risk-management program. Its first biosimilar, Tyruko, follows the same clinical framework. A transition therefore involves more than choosing another natalizumab brand. The prescriber, infusion site, insurer, and safety program all need to recognize the intended product so that monitoring and scheduled infusions continue correctly.

Tyruko is the only Tysabri biosimilar

As of August 2026, Tyruko (natalizumab-sztn) is the only FDA-approved biosimilar referencing Tysabri. The FDA approval announcement identifies Sandoz as the applicant and includes adult Crohn's disease among the approved uses. The FDA Purple Book record lists Tyruko as a 300 mg/15 mL intravenous product and a biosimilar without an interchangeable designation.

A non-interchangeable biosimilar can be prescribed and used like any other FDA-approved biosimilar. The designation means a pharmacy cannot rely on the federal interchangeability pathway to substitute it automatically for Tysabri. FDA still requires Tyruko to be highly similar to Tysabri, with no clinically meaningful difference in safety or effectiveness. A new infusion order should name Tyruko and natalizumab-sztn explicitly.

Confirm the product before every infusion by checking the appointment notice or asking the infusion nurse. The medication record should capture the brand, suffix, dose, date, and lot information used by the facility. This creates a clear treatment history for the gastroenterology team, insurer, and safety program. It also helps distinguish a product transition from a change in dosing or a delay caused by authorization, inventory, or scheduling.

Who can receive Tyruko for Crohn's disease

The current Tyruko prescribing information covers adults with moderately to severely active Crohn's disease who have evidence of inflammation and an inadequate response to, or inability to tolerate, conventional therapies and tumor necrosis factor inhibitors. It is used to induce and maintain clinical response and remission. The recommended dose is 300 mg infused over about one hour every four weeks.

The label states that Tyruko should not be used with immunosuppressants or TNF inhibitors in Crohn's disease. If a patient has not experienced therapeutic benefit by 12 weeks of induction treatment, the drug should be discontinued. Those requirements make medication reconciliation and follow-up timing especially important. The treating gastroenterologist should determine eligibility, response, and whether the broader treatment regimen is compatible with natalizumab.

The safety program shapes access

Natalizumab carries a boxed warning for progressive multifocal leukoencephalopathy, a rare brain infection that can cause severe disability or death. The label identifies anti-JC virus antibodies, longer treatment duration, and prior immunosuppressant use as factors that increase risk. Because of that risk, Tyruko is available only through the restricted TYRUKO REMS Program. The FDA-approved REMS document requires certified prescribers, pharmacies, and infusion sites, along with patient enrollment and periodic monitoring.

Before switching, confirm that the prescriber and infusion site can provide Tyruko through the program and that enrollment information is current. Keep copies of the medication guide, infusion dates, monitoring forms, and any JC virus antibody results discussed with the clinical team. New neurologic symptoms, changes in thinking or vision, weakness, or coordination problems require prompt medical evaluation under the label's safety instructions.

Ask who will complete each required form and when the next reassessment is due. Verify that the infusion site has the current prescriber's information and that the prescriber receives reports after each visit. If insurance redirects treatment to another site, confirm that the new facility is certified before transferring the appointment. Maintain one contact list for the REMS program, infusion center, gastroenterology office, and health plan so time-sensitive questions reach the correct party.

Insurance implications for Tyruko

Because Tyruko is administered at an infusion site, insurance commonly processes the drug and administration through the medical benefit. Medicare Part B generally covers biological products furnished incident to a physician's service, and CMS publishes biosimilar payment information. Commercial plans may use product-specific prior authorization, network, site-of-care, and step-therapy rules. Coverage should be checked directly with the plan before the first Tyruko infusion.

Ask whether the existing Tysabri authorization transfers, whether Tyruko has a separate billing code, whether the current site is in network and certified, and what deductible or coinsurance applies. The Crohn's & Colitis Foundation's biosimilar guidance recommends confirming when a change takes effect, where the product will be supplied, what it will cost, and what appeal options exist. For Tyruko, that insurance checklist should be coordinated with the REMS checklist to protect the four-week infusion schedule from an administrative mismatch.